Nutra Pharma Corp Stock Probability of Future Pink Sheet Price Finishing Over 9.6E-5

NPHC Stock  USD 0.0001  0.00  0.00%   
Nutra Pharma's future price is the expected price of Nutra Pharma instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Nutra Pharma Corp performance during a given time horizon utilizing its historical volatility. Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
  
Please specify Nutra Pharma's target price for which you would like Nutra Pharma odds to be computed.

Nutra Pharma Target Price Odds to finish over 9.6E-5

The tendency of Nutra Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to stay above $ 0.000096  in 90 days
 0.0001 90 days 0.000096 
about 38.75
Based on a normal probability distribution, the odds of Nutra Pharma to stay above $ 0.000096  in 90 days from now is about 38.75 (This Nutra Pharma Corp probability density function shows the probability of Nutra Pink Sheet to fall within a particular range of prices over 90 days) . Probability of Nutra Pharma Corp price to stay between $ 0.000096  and its current price of $1.0E-4 at the end of the 90-day period is roughly 2.71 .
Given the investment horizon of 90 days the pink sheet has the beta coefficient of 2.72 . This indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Nutra Pharma will likely underperform. Moreover Nutra Pharma Corp has an alpha of 1.1766, implying that it can generate a 1.18 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Nutra Pharma Price Density   
       Price  

Predictive Modules for Nutra Pharma

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Nutra Pharma Corp. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
0.000.00009950.01
Details
Intrinsic
Valuation
LowRealHigh
0.000.00009650.01
Details
Naive
Forecast
LowNextHigh
0.0000020.0001439.34
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.0000580.0000580.000058
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Nutra Pharma. Your research has to be compared to or analyzed against Nutra Pharma's peers to derive any actionable benefits. When done correctly, Nutra Pharma's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Nutra Pharma Corp.

Nutra Pharma Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Nutra Pharma is not an exception. The market had few large corrections towards the Nutra Pharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Nutra Pharma Corp, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Nutra Pharma within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
1.18
β
Beta against Dow Jones2.72
σ
Overall volatility
0.000056
Ir
Information ratio 0.09

Nutra Pharma Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Nutra Pharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Nutra Pharma Corp can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Nutra Pharma Corp is not yet fully synchronised with the market data
Nutra Pharma Corp is way too risky over 90 days horizon
Nutra Pharma Corp has some characteristics of a very speculative penny stock
Nutra Pharma Corp appears to be risky and price may revert if volatility continues
Nutra is showing solid risk-adjusted performance over 90 days
Nutra Pharma Corp currently holds 517.18 K in liabilities. Nutra Pharma Corp has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Nutra Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Nutra Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Nutra Pharma Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Nutra to invest in growth at high rates of return. When we think about Nutra Pharma's use of debt, we should always consider it together with cash and equity.
The entity reported the previous year's revenue of 51.9 K. Net Loss for the year was (769.18 K) with profit before overhead, payroll, taxes, and interest of 8.47 K.
Nutra Pharma Corp currently holds about 10.45 K in cash with (878.09 K) of positive cash flow from operations.

Nutra Pharma Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Nutra Pink Sheet often depends not only on the future outlook of the current and potential Nutra Pharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Nutra Pharma's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding6.6 B
Cash And Short Term Investments90.9 K

Nutra Pharma Technical Analysis

Nutra Pharma's future price can be derived by breaking down and analyzing its technical indicators over time. Nutra Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Nutra Pharma Corp. In general, you should focus on analyzing Nutra Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.

Nutra Pharma Predictive Forecast Models

Nutra Pharma's time-series forecasting models is one of many Nutra Pharma's pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Nutra Pharma's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.

Things to note about Nutra Pharma Corp

Checking the ongoing alerts about Nutra Pharma for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Nutra Pharma Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Nutra Pharma Corp is not yet fully synchronised with the market data
Nutra Pharma Corp is way too risky over 90 days horizon
Nutra Pharma Corp has some characteristics of a very speculative penny stock
Nutra Pharma Corp appears to be risky and price may revert if volatility continues
Nutra is showing solid risk-adjusted performance over 90 days
Nutra Pharma Corp currently holds 517.18 K in liabilities. Nutra Pharma Corp has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Nutra Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Nutra Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Nutra Pharma Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Nutra to invest in growth at high rates of return. When we think about Nutra Pharma's use of debt, we should always consider it together with cash and equity.
The entity reported the previous year's revenue of 51.9 K. Net Loss for the year was (769.18 K) with profit before overhead, payroll, taxes, and interest of 8.47 K.
Nutra Pharma Corp currently holds about 10.45 K in cash with (878.09 K) of positive cash flow from operations.

Other Information on Investing in Nutra Pink Sheet

Nutra Pharma financial ratios help investors to determine whether Nutra Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nutra with respect to the benefits of owning Nutra Pharma security.